Participation in these studies must be in compliance with your local ethical and patient consent guidelines.
Pre- and Post-Transplant Serum Biomarker Studies
Introduction
Pre- and post-transplant determination of a recipient's risk of graft rejection is a prerequisite for the application of recipient-tailored immunosuppression in organ transplantation. Previous findings indicate that HLA antibodies and T-cell activation marker soluble CD30 (sCD30) are useful parameters for risk estimation. These high molecular weight proteins are not overly sensitive to degradation. Serum samples can therefore be used for research studies even after prolonged frozen storage. Availability of recipient and donor DNA samples is important for the reliable detection of donor-specific antibodies against different HLA and non-HLA loci.
Goal of the study
The goal of the CTS Serum Studies is to elucidate the complex interactions between easily detectable biomarkers and outcome parameters. The outcome measure "graft loss" has become a rare event and several confounders influence the outcome in organ transplantation. It is therefore necessary to study large series of patients. You can also participate only in the "Pre-Transplant Serum Study" or in the "Post-Transplant Serum Study" in which, however, a pretransplant serum is also required to evaluate the impact of de novo antibody development.